Clinical Trial Update: Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Zevor-cel (CT053) in relapsed/refractory multiple myeloma (LUMMICAR STUDY 2) spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Zevor-cel (CT053)

Snippet

Sponsor: CARsgen Therapeutics Co., Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING